Being for the $11.9bn benefit of investors of Kite: Gilead jumps into CAR T – In-PharmaTechnologist.com
Being for the $11.9bn benefit of investors of Kite: Gilead jumps into CAR TIn-PharmaTechnologist.comGilead will also add a chimeric antigen receptor (CAR) T-cell manufacturing facility in El Segunda, California which opened in June last year and has th… Continue reading
